Frequently Asked Questions
What does OmniParticles do?
OmniParticles is the world's first nanomedicine CDMO and a clinical-phase fill-finish CMO, based in Seoul, South Korea. We develop and manufacture nanoparticle drug substances and provide aseptic fill-finish of clinical-phase drug product at our Seoul site.
What drug substance services do you offer?
End-to-end development of nanoparticle drug substances, covering concept translation, formulation, scale-up of more than 1,000-fold from research batches, and GMP-compliant manufacturing with CMC support.
What types of nanoparticles can you work with?
Candidate cores include small molecules, proteins and peptides, biologics and antibodies, DNA/RNA, and inorganic materials such as cerium oxide, iron oxide, gold, silver, platinum and silica. These can be combined with polymer, lipid, liposome or silica surfaces on our INNOSURFACE® platform.
What fill-finish capacity do you have?
Aseptic fill-finish of preclinical to Phase III clinical batches of 2,000–5,000 vials (20–50 L), at 25–50 vials per minute, into 10 mL ready-to-use vials. There is no commercial-scale minimum.
What are the aseptic filling conditions?
Grade A filling in open RABS within a Grade B background, aligned with EU GMP Annex 1. The product-contact train is fully single-use, with 0.2 µm sterilising filtration and PUPSIT.
Can you fill products that are not nanoparticles?
Yes, subject to a product-specific facility fit and risk assessment. Supported modalities include small molecules, biologics, ATMPs / cell and gene therapies, ADCs, RNA therapeutics, oligonucleotides, peptides, monoclonal antibodies, viral vectors, radiopharmaceutical cold kits and some cytotoxic products. Suspensions, viscous and light- or oxygen-sensitive products are assessed rather than declined.
Can you take over an existing fill-finish process?
Yes. Tech transfer includes measured process fit assessment on our line, full reporting of findings, batch record preparation and documented change control.
What analytical capabilities do you have in-house?
DLS, TEM, zeta potential, UV-Vis, ICP-MS (down to parts per trillion), LC-MS, GPC and HPLC (including SEC mode, triple detector).
Do you provide regulatory and CMC documentation?
Yes. We prepare CMC documentation and CTD Module 3 sections for FDA, EMA and MFDS filings. Our team supported a cerium oxide nanomedicine through FDA IND clearance.
How are clinical batches released?
Batches are released under cGMP and EU GMP requirements with batch records, manufacturing reports and certificates of analysis. Sterility testing is performed in-house in a Grade B suite, together with 100% visual inspection.
How do we start a project?
Contact us at cdmo@omniparticles.com with a short description of your material and stage. We provide services on a fee-for-service basis.
